Aristo Bio-Tech & Lifescience Ltd
ARISTO NSE
Aristo Bio-Tech & Lifescience Ltd
ChemicalsNSE: ARISTO Pesticides & Agrochemicals
Key Fundamentals
SMEPesticides & AgrochemicalsChemicalsMarket Cap
₹70.12 Cr
Volatility
Moderate
P/E Ratio
9.8
EBITDA
₹16.05 Cr
Return on Equity
10.88%
Debt to Equity
0.78
Book Value
₹65.39
52W High
₹140
52W Low
₹74.3
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aristo Bio-Tech & Lifescience Ltd insights
33 extracted metrics + investor summaries across FY16–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 46.1% CAGR over last 5 years
Weaknesses
1- Company has a low return on equity of 13.9% over last 3 years.
Growth Rate
Revenue Growth
14.20% ↗
Net Income Growth
73.66% ↘
Cash Flow Change
31.84% ↗
ROE
-6.13% ↘
ROCE
-2.59% ↘
EBITDA Margin (Avg.)
44.59% ↗
Quarterly Results
| Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 129 | 89 | 133 | 112 | 214 | 104 | 256 | 107 |
| Expenses | 72 | 124 | 85 | 128 | 109 | 206 | 103 | 249 | 99 |
| Operating Profit | 1 | 5 | 4 | 5 | 3 | 8 | 1 | 8 | 8 |
| OPM % | 1.2% | 3.9% | 4.1% | 4% | 2.9% | 3.8% | 1.1% | 3.1% | 8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | -1 | 4 | 1 | 4 | 2 | 6 | -1 | 6 | 4 |
| Tax % | -35% | 28% | 13% | 28% | 27% | 25% | -18% | 25% | 27% |
| Net Profit | 0 | 3 | 1 | 3 | 1 | 5 | 0 | 4 | 3 |
| EPS in Rs | -0.48 | 3.8 | 1.47 | 3.78 | 1.94 | 6.68 | -0.72 | 6.13 | 4.42 |
Profit & Loss
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 159 | 271 | 202 | 201 | 167 | 166 | 218 | 245 | 318 | 364 |
| Expenses | 56 | 157 | 263 | 195 | 197 | 163 | 160 | 209 | 236 | 309 | 348 |
| Operating Profit | 1 | 3 | 7 | 7 | 5 | 4 | 5 | 9 | 8 | 9 | 16 |
| OPM % | 1.6% | 1.6% | 2.7% | 3.4% | 2.2% | 2.6% | 3.3% | 4% | 3.5% | 2.9% | 4.4% |
| Other Income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| PBT | 1 | 3 | 6 | 4 | 1 | 2 | 2 | 5 | 5 | 5 | 10 |
| Tax % | 33% | 31% | 34% | 31% | 28% | 28% | 28% | 25% | 28% | 26% | 26% |
| Net Profit | 0 | 2 | 4 | 3 | 1 | 1 | 1 | 4 | 4 | 4 | 7 |
| EPS in Rs | 4 | 18.52 | 37.44 | 5.67 | 2.02 | 2.16 | 2.14 | 5.23 | 5.73 | 5.96 | 10.55 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 7% | 8% | 6% |
Balance Sheet
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 7 | 7 | 7 | 7 |
| Reserves | 2 | 4 | 7 | 6 | 7 | 8 | 10 | 23 | 27 | 31 | 38 |
| Borrowings | 5 | 10 | 20 | 14 | 20 | 22 | 25 | 22 | 21 | 22 | 35 |
| Other Liabilities | 20 | 72 | 60 | 65 | 56 | 46 | 37 | 47 | 73 | 81 | 75 |
| Total Liabilities | 27 | 87 | 89 | 91 | 88 | 81 | 77 | 100 | 127 | 141 | 155 |
| Fixed Assets | 2 | 2 | 8 | 8 | 8 | 12 | 14 | 16 | 22 | 24 | 24 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 25 | 85 | 81 | 81 | 77 | 69 | 63 | 83 | 106 | 117 | 131 |
| Total Assets | 27 | 87 | 89 | 91 | 88 | 81 | 77 | 100 | 127 | 141 | 155 |
Cash Flow
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | -4 | 1 | 8 | 1 | 2 | 7 | -3 | 8 | 10 | 8 |
| Investing | — | 0 | -5 | -2 | -2 | -2 | -3 | -4 | -7 | -5 | -3 |
| Financing | — | 4 | 4 | -6 | 1 | -1 | -3 | 8 | -2 | -4 | -4 |
| Net Cash Flow | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 0 | 2 |
| Free Cash Flow | — | -4 | 0 | 6 | -1 | 0 | 4 | -7 | 1 | 5 | 5 |
| CFO/OP | — | -123 | 38 | 138 | 40 | 60 | 134 | -17 | 106 | 123 | 69 |
Ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 121 | 65 | 77 | 88 | 72 | 73 | 75 | 86 | 65 | 55 |
| Inventory Days | 66 | 67 | 42 | 65 | 47 | 78 | 60 | 57 | 65 | 59 | 70 |
| Days Payable | 142 | 177 | 85 | 124 | 74 | 93 | 87 | 85 | 112 | 97 | 78 |
| Cash Conversion Cycle | 16 | 11 | 23 | 18 | 61 | 56 | 46 | 48 | 38 | 26 | 46 |
| Working Capital Days | 3 | 14 | 14 | 15 | 20 | 28 | 25 | 37 | 31 | 22 | 25 |
| ROCE % | — | 31% | 34% | 24% | 14% | 11% | 12% | 16% | 13% | 12% | 20% |
Documents
1
Certificate under SEBI (Depositories and Participants) Regulations, 2018
7 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. 7 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
2
Outcome of Board Meeting
30 May - Board approved FY26 audited results, unmodified audit opinion, and recommended Rs0.60 final dividend per share. 30 May - Board approved FY26 audited results, unmodified audit opinion, and recommended Rs0.60 final dividend per share.
3
Dividend
30 May - Board approved FY26 audited results, recommended Rs0.60 final dividend, and reported unmodified audit opinion. 30 May - Board approved FY26 audited results, recommended Rs0.60 final dividend, and reported unmodified audit opinion.
4
Structural Digital Database
28 May - Submitted SDD compliance certificate for FY2026 under SEBI PIT Regulations. 28 May - Submitted SDD compliance certificate for FY2026 under SEBI PIT Regulations.
5
Disclosure under SEBI Takeover Regulations
25 May - Narendra Singh Barhat has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, … 25 May - Narendra Singh Barhat has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
Frequently Asked Questions about Aristo Bio-Tech & Lifescience Ltd
What does Aristo Bio-Tech & Lifescience Ltd do?
Incorporated in 2005, Aristo Bio-Tech and Lifescience Ltd manufactures and supplies pesticides and agrochemicals[1]
Where is Aristo Bio-Tech & Lifescience Ltd (ARISTO) listed?
Aristo Bio-Tech & Lifescience Ltd is listed on the Indian stock exchanges. It is listed on NSE: ARISTO. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Aristo Bio-Tech & Lifescience Ltd belong to?
Aristo Bio-Tech & Lifescience Ltd operates in the Chemicals sector within the Pesticides & Agrochemicals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Aristo Bio-Tech & Lifescience Ltd?
Aristo Bio-Tech & Lifescience Ltd has a market capitalisation of approximately ₹70.12 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Aristo Bio-Tech & Lifescience Ltd?
The Price-to-Earnings (PE) ratio of Aristo Bio-Tech & Lifescience Ltd is 9.80. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Aristo Bio-Tech & Lifescience Ltd?
Over the past 52 weeks, Aristo Bio-Tech & Lifescience Ltd has traded between a low of ₹74.3 and a high of ₹140. This range helps investors understand the stock's price volatility and recent trading levels.
Does Aristo Bio-Tech & Lifescience Ltd pay dividends?
Yes, Aristo Bio-Tech & Lifescience Ltd has a dividend yield of 0.49%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Aristo Bio-Tech & Lifescience Ltd?
Aristo Bio-Tech & Lifescience Ltd has a Return on Equity (ROE) of 10.88%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Aristo Bio-Tech & Lifescience Ltd on Tapetide?
On Tapetide, you can view Aristo Bio-Tech & Lifescience Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2005, Aristo Bio-Tech and Lifescience Ltd manufactures and supplies pesticides and agrochemicals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ARISTO.md for Aristo Bio-Tech & Lifescience Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.